TWI609882B - 雙特異性抗體及其使用方法 - Google Patents

雙特異性抗體及其使用方法 Download PDF

Info

Publication number
TWI609882B
TWI609882B TW102117991A TW102117991A TWI609882B TW I609882 B TWI609882 B TW I609882B TW 102117991 A TW102117991 A TW 102117991A TW 102117991 A TW102117991 A TW 102117991A TW I609882 B TWI609882 B TW I609882B
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
antibody
bispecific antibody
binding
Prior art date
Application number
TW102117991A
Other languages
English (en)
Chinese (zh)
Other versions
TW201350503A (zh
Inventor
布蘭達Ｌ 史帝芬斯
Brenda L. Stevens
愛力森 懷特
Alison Witte
馬克Ｍ 瑞克森
Mark W. Rixon
約瑟芬妮Ｍ 卡達利
Josephine M. Cardarelli
湯瑪士Ｄ 坎普
Thomas D. Kempe
史考特Ｒ 普瑞斯尼爾
Scott R. Presnell
摩漢 史林維桑
Mohan Srinivasan
蘇珊Ｃ 汪
Susan C. WONG
陳國棟
Guodong Chen
魏徽
Hui WEI
史丹利Ｒ 克萊史帝克
Stanley R. Krystek
陸梅爾Ａ 許尼維司
Lumelle A. SCHNEEWEIS
保羅Ｏ 史帕德
Paul O. Sheppard
印德拉尼 恰克拉波提
Indrani CHAKRABORTY
高曼
Mian Gao
史帝芬 薛夫
Steven Sheriff
諾哈 迪托
Noah DITTO
尼爾斯Ｓ 漢默奇
Nels B. HAMACHER
湯瑪士 艾德華茲
Thomas Edwards
卡特里 艾金斯
Kateri ATKINS
崔西 阿卡奇
Tracy ARAKAKI
Original Assignee
必治妥美雅史谷比公司
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 必治妥美雅史谷比公司, Bristol-Myers Squibb Company filed Critical 必治妥美雅史谷比公司
Publication of TW201350503A publication Critical patent/TW201350503A/zh
Application granted granted Critical
Publication of TWI609882B publication Critical patent/TWI609882B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
TW102117991A 2012-05-22 2013-05-21 雙特異性抗體及其使用方法 TWI609882B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261650286P 2012-05-22 2012-05-22
US61/650,286 2012-05-22
US201361784600P 2013-03-14 2013-03-14
US61/784,600 2013-03-14
US201361787890P 2013-03-15 2013-03-15
US61/787,890 2013-03-15

Publications (2)

Publication Number Publication Date
TW201350503A TW201350503A (zh) 2013-12-16
TWI609882B true TWI609882B (zh) 2018-01-01

Family

ID=48539425

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102117991A TWI609882B (zh) 2012-05-22 2013-05-21 雙特異性抗體及其使用方法

Country Status (11)

Country Link
US (8) US9708401B2 (de)
EP (2) EP3456741B1 (de)
JP (1) JP6362587B2 (de)
CN (1) CN104884473B (de)
AR (1) AR091116A1 (de)
ES (2) ES2711554T3 (de)
LT (1) LT2852615T (de)
SI (1) SI2852615T1 (de)
TW (1) TWI609882B (de)
UY (1) UY34815A (de)
WO (1) WO2013177101A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
CA2646478A1 (en) 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2015143123A2 (en) 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
US20170022291A1 (en) 2014-04-01 2017-01-26 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
MY186389A (en) * 2014-05-13 2021-07-22 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
SG11201610074YA (en) 2014-06-06 2016-12-29 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2016014761A1 (en) * 2014-07-24 2016-01-28 Academia Sinica Diagnosis and treatment of kawasaki disease
US20170152323A1 (en) * 2015-01-16 2017-06-01 Immunwork Inc. Anti-inflammatory molecules with tissue-targeting functions
JP2018506275A (ja) * 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
JP6812364B2 (ja) 2015-06-03 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌診断用抗ｇｉｔｒ抗体
WO2017004149A1 (en) * 2015-06-30 2017-01-05 Boehringer Ingelheim International Gmbh Multi-specific binding proteins
SG10201912593VA (en) * 2015-07-23 2020-02-27 Boehringer Ingelheim Int Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
JP6966424B2 (ja) 2015-09-09 2021-11-17 フレッド ハッチンソン キャンサー リサーチ センター 軟骨ホーミングペプチド
EA201891121A1 (ru) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
CA3036913C (en) 2016-09-14 2023-05-16 Beijing Hanmi Pharm. Co., Ltd. Antibody specifically binding to il-17a and functional fragment thereof
AU2017402210B2 (en) * 2017-03-10 2021-08-19 Suzhou Kanova Biopharmaceutical Co., Ltd. Monoclonal antibody against both IL-17A and IL-17F and use of the same
EP3595699A4 (de) * 2017-03-16 2020-12-23 Blaze Bioscience, Inc. Knorpel-homing-peptidkonjugate und verfahren zur verwendung davon
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
CN107384960B (zh) * 2017-07-25 2020-06-12 吉优诺（上海）基因科技有限公司 基于复制缺陷性重组腺病毒携带il-17结合分子转基因载体及其构建方法和应用
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
JP2021501752A (ja) 2017-11-02 2021-01-21 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用して腱障害を治療する方法
KR102048475B1 (ko) * 2017-11-10 2019-11-26 주식회사 와이바이오로직스 IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN108929903B (zh) * 2018-04-23 2021-07-16 东莞市第五人民医院(东莞市太平人民医院) 用于慢性牙周炎筛查、诊断、疗效评价的标志物及试剂盒
CN112334483B (zh) * 2018-11-27 2022-05-10 信达生物制药(苏州)有限公司 抗IL-23p19抗体及其用途
EP3897719A4 (de) * 2018-12-21 2022-11-02 Zhejiang Shimai Pharmaceutical Co., Ltd. Durch protease spaltbare bispezifische antikörper und verwendungen davon
CN110330566A (zh) * 2019-06-11 2019-10-15 南京华岩生物技术有限公司 一种具有双重可变结构域的双特异性结合的免疫球蛋白
WO2021222316A2 (en) * 2020-04-27 2021-11-04 Twist Bioscience Corporation Variant nucleic acid libraries for coronavirus
WO2021238932A1 (zh) * 2020-05-26 2021-12-02 百奥泰生物制药股份有限公司 多特异性抗体及其应用
CN112807428A (zh) 2020-06-12 2021-05-18 江苏荃信生物医药有限公司 包含抗人白介素23单克隆抗体的药物组合物
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299129A1 (en) * 2006-03-10 2008-12-04 Lewis Katherine E Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5658739A (en) 1994-05-10 1997-08-19 The Regents Of The University Of California Method for characterization of the fine structure of protein binding sites
US6291189B1 (en) 1994-05-10 2001-09-18 Carta Proteomics, Inc. Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
JP2002510644A (ja) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
ATE474849T1 (de) 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
IL145134A0 (en) 1999-03-25 2002-06-30 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
US20030199041A1 (en) 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
EP1641822B1 (de) 2003-07-08 2013-05-15 Genentech, Inc. Heterologe il-17-a/f-polypeptide und therapeutische anwendungen davon
NZ599196A (en) * 2003-07-15 2014-01-31 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
CN102174581B (zh) 2003-12-09 2013-04-17 诺维信股份有限公司 消除或减少丝状真菌菌株基因表达的方法
JP2007535930A (ja) 2004-05-03 2007-12-13 シェーリング　コーポレイション 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
US7910540B2 (en) 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AU2006214473A1 (en) 2005-02-14 2006-08-24 Wyeth Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
TR201902033T4 (tr) 2005-06-30 2019-03-21 Janssen Biotech Inc Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EA013506B1 (ru) 2005-08-25 2010-06-30 Эли Лилли Энд Компани Антитело к il-23 и его применение
US7807160B2 (en) 2005-08-31 2010-10-05 Schering Corporation Engineered anti-IL-23 antibodies
JP2009507023A (ja) 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
PL2481753T3 (pl) * 2005-12-13 2018-09-28 Eli Lilly And Company Przeciwciała anty-IL-17
WO2007117749A2 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
CA2646478A1 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
TWI390034B (zh) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
JP5118699B2 (ja) 2006-08-11 2013-01-16 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｌ−１７ａに対する抗体
WO2008133684A1 (en) 2007-04-27 2008-11-06 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
EP2150564A2 (de) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Il-17a-, il-17f- und il-23p19-antagonisten und verwendungsverfahren
EP2535349A1 (de) * 2007-09-26 2012-12-19 UCB Pharma S.A. Antikörperfusionen mit Doppelspezifität
WO2009131239A1 (ja) 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
WO2009136286A2 (en) 2008-05-05 2009-11-12 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
AU2009256250B2 (en) * 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
MX341309B (es) * 2010-07-20 2016-08-12 Cephalon Australia Pty Ltd Anticuerpos especificos del heterodimero de anti-il-23.
JP2014533249A (ja) * 2011-11-07 2014-12-11 メディミューン，エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299129A1 (en) * 2006-03-10 2008-12-04 Lewis Katherine E Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Andrew C. Chan et al., "Therapeutic antibodies for autoimmunity and inflammation", NATURE REVIEWS Immunology, VOL 10, MAY 2010, 301-316. *

Also Published As

Publication number Publication date
TW201350503A (zh) 2013-12-16
US11254740B2 (en) 2022-02-22
EP3456741B1 (de) 2020-12-16
US9708401B2 (en) 2017-07-18
UY34815A (es) 2013-11-29
US20170275357A1 (en) 2017-09-28
LT2852615T (lt) 2019-02-11
US20200040072A1 (en) 2020-02-06
CN104884473B (zh) 2019-12-03
SI2852615T1 (sl) 2019-02-28
AR091116A1 (es) 2015-01-14
EP2852615B1 (de) 2018-12-05
US20220185877A1 (en) 2022-06-16
US10358489B2 (en) 2019-07-23
US20180037645A1 (en) 2018-02-08
US8945553B2 (en) 2015-02-03
EP2852615A2 (de) 2015-04-01
US20150099278A1 (en) 2015-04-09
WO2013177101A3 (en) 2014-05-15
ES2711554T3 (es) 2019-05-06
WO2013177101A2 (en) 2013-11-28
JP2015520169A (ja) 2015-07-16
US20130315911A1 (en) 2013-11-28
CN104884473A (zh) 2015-09-02
JP6362587B2 (ja) 2018-07-25
US9783606B2 (en) 2017-10-10
US10358490B2 (en) 2019-07-23
US20150086552A1 (en) 2015-03-26
ES2846623T3 (es) 2021-07-28
US20170022272A1 (en) 2017-01-26
EP3456741A1 (de) 2019-03-20

Similar Documents

Publication Publication Date Title
US11254740B2 (en) Methods of treatment using IL-23p19 monoclonal antibodies
AU2016370659B2 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
JP5898653B2 (ja) 抗ｉｌ１７ａ／ｉｌ−１７ｆ交差反応抗体及びその使用方法
MX2011001909A (es) Anticuerpos anti-interleucina-13 modificados, composiciones, metodos y usos.
US20210238294A1 (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
JP6380394B2 (ja) 新規抗ヒトｔｓｌｐ受容体抗体
TW202144433A (zh) 抗體或其抗原結合片段、其製備方法及醫藥用途
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
WO2021209066A1 (zh) 特异性抗原结合分子，其制备方法及医药用途

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees